ASCO: Clovis stock doubles on possible ''breakthrough'' lung cancer drug
This article was originally published in Scrip
Executive Summary
Investors doubled the value of Clovis Oncology on 3 June to close up 103.9% at $74.59 per share based on positive Phase I data from six lung cancer patients treated with the Boulder, Colorado-based company's EGFR inhibitor CO-1686, which may be a candidate for the US FDA's breakthrough therapy designation.
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal
Deal Snapshot: Ipsen committed up to $1.8bn in upfront and milestone fees to develop novel treatments for rare neurological diseases with Skyhawk’s RNA-targeting small molecule platform.